Inclusion Criteria:

- Male or female subjects >/= 18 years of age

- Life expectancy of at least 3 months

- Histological or cytological documentation of adenocarcinoma of the colon or rectum

- Subjects with metastatic colorectal cancer (Stage IV)

- Progression during or within 3 months following the last administration of approved
standard therapies which must include fluoropyrimidine, oxaliplatin, irinotecan,
bevacizumab and cetuximab/panitumumab if KRAS WT (WT: wild-type i.e. no KRAS
mutation)

- Eastern Cooperative Oncology Group (ECOG) Performance Status of
- Adequate bone marrow, liver and renal function as assessed by the following
laboratory requirements

- Women of childbearing potential and men must agree to use adequate contraception
since signing of the inform consent (IC) form until at least 3 months after the last
study drug administration

Exclusion Criteria:

- Prior treatment with regorafenib

- Major surgical procedure, open biopsy, or significant traumatic injury within 28 days
before start of study drug

- Pregnant or breast-feeding subjects

- Congestive heart failure >/= New York Heart Association (NYHA) class 2

- Myocardial infarction less than 6 months before start of study drug

- Ongoing infection > Grade 2 Common Terminology Criteria for Adverse Events (CTCAE) v.
4.0

- Renal failure requiring hemo-or peritoneal dialysis